Moderna (MRNA) Invested Capital (2016 - 2026)

Moderna (MRNA) has 11 years of Invested Capital data on file, last reported at $7.5 billion in Q1 2026.

• Invested Capital for Q1 2026 came in at $7.5 billion, down 26.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.5 billion (down 26.43% YoY), and the FY2025 annual result was $9.2 billion, down 15.72% from the prior year.
• Invested Capital fell to $7.5 billion in Q1 2026 per MRNA's latest filing, from $9.2 billion in the prior quarter.
• Over five years, Invested Capital peaked at $20.2 billion in Q4 2022 and troughed at $7.5 billion in Q1 2026.
• A 5-year average of $14.0 billion and a median of $13.4 billion in 2024 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2022 and 2024: Invested Capital soared 344.69% in 2022, then plunged 32.52% in 2024.
• A 5-year view of Invested Capital shows it stood at $20.2 billion in 2022, then retreated by 28.56% to $14.4 billion in 2023, then declined by 24.02% to $11.0 billion in 2024, then slipped by 15.72% to $9.2 billion in 2025, then fell by 19.35% to $7.5 billion in 2026.
• Business Quant data shows MRNA's Invested Capital at $7.5 billion in Q1 2026, $9.2 billion in Q4 2025, and $9.4 billion in Q3 2025.